Technology | October 03, 2013

Beckman Coulter Receives FDA Clearance of AccuTnI+3 Troponin I Assay on UniCel DxI Immunoassay Systems

Cardiac Disease Management Assay Available on Entire Immunoassay Portfolio

blood testing cath lab beckman coulter danaher

October 3, 2013 — Delivering the precision, clinical sensitivity and clinical specificity necessary to assist physicians with the diagnosis of myocardial infarction (MI), Beckman Coulter Inc. announced the U.S. Food and Drug Administration (FDA) clearance of its new Access AccuTnI+3 troponin I assay for use on the UniCel DxI series of immunoassay systems.

Following the June 2013 clearance of the Access AccuTnI+3 troponin I assay on Beckman Coulter's Access 2 immunoassay analyzer, the new troponin assay is now cleared for use on all of the company's immunoassay systems, as well as the UniCel DxC integrated chemistry and immunoassay series.

"The AccuTnI+3 troponin assay has been clinically proven through a large multi-center study that enrolled more than 1,900 subjects, and it is confirmed that the test provides the clinical performance needed for optimal patient management," said Arnd Kaldowski, president, Beckman Coulter Diagnostics. "Our new troponin I assay is directly aligned with the FDA's October 2010 guidance to manufacturers of troponin assays and confirms our commitment to modernize the performance evaluation of this critical test."

AccuTnI+3 delivers clinical sensitivity and specificity aligned with contemporary use of troponin set forth by the FDA and utilizes platform-specific reagents and calibrators.

For more information: www.beckmancoulter.com, www.danaher.com

Related Content

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
News | Blood Testing | March 22, 2016
March 22, 2016 — Critical Diagnostics announced that it entered into a license agreement for the exclusive worldwide
Overlay Init